Menu
The Goodman Institute Health Blog
  • Home
  • Authors
    • Devon Herrick, Ph.D.
    • John C. Goodman
  • Popular Topics
    • Hits & Misses
    • Artificial Intelligence and Healthcare
    • Doctors & Hospitals
      • COVID-19 and Public Health
    • Policy & Legislation
      • Affordable Care Act
    • Health Economics & Costs
      • Cost of Healthcare
      • Drug Prices & Regulations
      • Health Reform
    • Health Insurance
      • Public Insurance
      • Medicare
    • Telemedicine
      • Medical Tourism
  • Goodman Institute
  • Contact
  • Search
The Goodman Institute Health Blog

Category: Drug Prices & Regulations

Health Affairs: A Bad Job Can Make You Feel Bad

Posted on July 28, 2023 by Devon Herrick

In popular culture the notion of an undesirable employment situation having a negative impact on one’s health is common. We have all heard friends and colleagues say, “that job is going to kill me” or “my boss is driving me crazy.” People the world over spend so much time at work that work is often highly associated with self-identity. Research is increasingly finding our popular notions are indeed true. A bad job can kill you, make you feel depressed and sometimes physically ill.

+

Nature: Many Clinical Trials Fake Data

Posted on July 26, 2023 by Devon Herrick

Did that drug you just took flunk its clinical trial? How about the course of treatment your doctor just recommended? Of course, you don’t know that because you have faith in the regulatory bodies, academic journals and researchers to be both competent and honest. And, of course, you know nothing of the perverse incentives to…

+

Wednesday Links

Posted on July 26, 2023July 26, 2023 by John C. Goodman
  • Lawsuit: Cigna algorithm rejects claims without a doctor even opening a patient’s records.
  • Report: CMS’ Medicaid inflation penalty will make generic drug shortages worse.
  • Virginia Medicaid paid at least $21.8 million on behalf of 12,054 enrollees after they were already dead.
  • An expensive trip: a medically approved, psychedelic renaissance is underway.
  • Did Gilead hold a promising HIV drug off the market in order to increase profits? (NYT) Economic theory would say no.
  • Australia has “virtually eliminated” HIV transmission in Sydney and elsewhere.
+

Regulations and Patent Gaming Undermines Drug Maker Competition, Delays New Products

Posted on July 24, 2023July 23, 2023 by Devon Herrick

Yesterday John Goodman posted a link about pharmaceutical companies gaming the patent system. The following is an excerpt from the American Institute for Economic Research:

Senator Bernie Sanders isn’t right about much, but he is about one thing: The United States pays too much for prescription drugs.

… [t]here are also many bad US government policies putting upward pressure on domestic drug prices.

The fundamental issue is that there is no free market in the drug industry. It’s been steadily eroded by regulators and lawmakers, often at the behest and to the benefit of drug manufacturers, resulting in their ability to charge prices well over what a competitive market would allow.

Much of the blame for a lack of market competition can also be attributed to a U.S. patent system that is too easily gamed and exploited by drug companies.

+
  • Previous
  • 1
  • …
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • …
  • 237
  • Next

For many years, our health care blog was the only free enterprise health policy blog on the internet. Then, when the NCPA closed its doors, the health blog stopped as well.

During this five-year hiatus no one else has come forward to claim the space. So, my colleagues and I have decided to restart the blog in connection with the Goodman Institute. We invite you and others to use this forum to share your views.

John C. Goodman,

Visit www.goodmaninstitute.org

Subscribe via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 42 other subscribers

Popular Topics

©2026 The Goodman Institute Health Blog | Website by Lexicom